ARS Pharmaceuticals Inc（SPRY）财务数据SPRYARS Pharmaceuticals Inc

Evaluating the bottom line, ARS Pharmaceuticals, Inc. maintains a gross margin of 61.83%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -182.62%, while the net margin is -185.21%. These profitability ratios, combined with a Return on Equity (ROE) of -210.35%, provide a clear picture of how effectively SPRY converts its operational activities into shareholder value.

In the context of the broader market, SPRY competes directly with industry leaders such as EIKN and INDP. With a market capitalization of $400.77M, it holds a significant position in the sector. When comparing efficiency, SPRY's gross margin of 61.83% stands against EIKN's N/A and INDP's N/A. Such benchmarking helps identify whether ARS Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

The financial performance shows a significant decline in net income, with losses increasing from $49.9 million in Q4 2024 to $62.3 million in Q2 2026. Gross margins have also decreased from 99% to 61.83% over the same period, indicating potential challenges in maintaining profitability.